Comparative Pharmacology
Head-to-head clinical analysis: EBGLYSS versus MAVYRET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EBGLYSS versus MAVYRET.
EBGLYSS vs MAVYRET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ebglyss is a monoclonal antibody that binds to the A subunit of interleukin-13 (IL-13), blocking its interaction with the IL-13 receptor. This inhibits IL-13-mediated signaling, reducing inflammation and skin barrier dysfunction in atopic dermatitis.
Fixed-dose combination of glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) that directly inhibits HCV viral replication by targeting viral proteins essential for polyprotein processing and RNA replication.
EBGLYSS (lebrikizumab-lbkz) is administered subcutaneously. Loading dose: 500 mg (two 250 mg injections) at week 0 and week 2. Maintenance dose: 250 mg every 2 weeks thereafter.
Three tablets (containing glecaprevir 100 mg and pibrentasvir 40 mg) taken orally once daily with food for 8 to 16 weeks depending on patient characteristics and prior treatment history.
None Documented
None Documented
Terminal elimination half-life ranges from 90 to 110 hours (~4 days). This long half-life supports weekly subcutaneous dosing; steady-state concentrations are achieved after approximately 14 weeks of weekly administration.
Glecaprevir: 6 hours; pibrentasvir: 13 hours; supports once-daily dosing.
Primarily through biliary/fecal route (approximately 70% of absorbed dose as unchanged drug in feces), with approximately 30% renally eliminated (mostly as metabolites). Less than 5% of the administered dose is excreted unchanged in urine.
Primarily fecal (92%) with unchanged drug (50.3% glecaprevir, 63.8% pibrentasvir); renal elimination is minimal (<1%).
Category C
Category C
Antiviral Agent
Antiviral Agent